These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 20483049)

  • 1. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
    Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
    Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
    Agirbasli M; Inanc N; Baykan OA; Direskeneli H
    Clin Exp Rheumatol; 2006; 24(5):580-3. PubMed ID: 17181930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
    Antoni C; Kalden JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].
    Wiland P; Głowska A; Chlebicki A; Szechiński J
    Pol Arch Med Wewn; 2002 Nov; 108(5):1055-63. PubMed ID: 12685246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(4):373-9. PubMed ID: 16956426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis.
    Kopp S; Alstergren P; Ernestam S; Nordahl S; Morin P; Bratt J
    Cells Tissues Organs; 2005; 180(1):22-30. PubMed ID: 16088130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
    Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis.
    Del Porto F; Laganà B; Lai S; Nofroni I; Tinti F; Vitale M; Podestà E; Mitterhofer AP; D'Amelio R
    Rheumatology (Oxford); 2007 Jul; 46(7):1111-5. PubMed ID: 17449484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Watt I; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Schaardenburg D; van Krugten MV; Dijkmans BA; Huizinga TW; Lems WF; Kloppenburg M
    Osteoarthritis Cartilage; 2010 Oct; 18(10):1256-62. PubMed ID: 20691795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.